Mediar Therapeutics Secures $76 Million for Clinical Data Collection on Three Experimental Medicines

Mediar Therapeutics, a biotechnology company focused on fibrosis, has successfully raised $76 million in a recent funding round. This capital is designated to facilitate the collection of clinical data for three experimental medicines developed by the company. The data collection is projected to occur over the next two years.